ArticleCancer medicine2026
Epidemiological Characterizations and Diagnostic Strategies Variation in Parotid Gland Tumors (2010-2024): Observations Based on 2133 Cases.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo analyze epidemiological trends and diagnostic approaches for parotid gland tumors (PGTs) from 2010 to 2024 and predict future trends.
methodsA total of 2591 surgically and pathologically confirmed PGTs were reviewed. After excluding metastatic tumors, non-neoplastic lesions, hematolymphoid tumors, and other non-epithelial lesions, 2133 primary epithelial PGTs were included. Temporal trends in the benign-to-malignant ratio and the distribution of pathological subtypes were analyzed across five consecutive 3-year intervals. An autoregressive moving average (ARMA) model was employed to forecast future trends. The diagnostic performance of ultrasonography, CT, and MRI was subsequently evaluated.
resultsBenign tumors comprised 88.0% (n = 1876), with Warthin tumor (WT, 48.5%) surpassing pleomorphic adenoma (PA, 40.7%). Malignant tumors constituted 12.0% (n = 257), with mucoepidermoid carcinoma predominating (27.8%). The proportion of WTs increased over time and is projected to rise further, while malignant tumors are expected to reach a plateau at around 11%. WT was most common in older males (51-70 years), whereas PA predominated in females. MRI showed the highest sensitivity for malignancy (51%) but moderate specificity (81%). CT had a sensitivity of 39% and specificity of 87%. Ultrasound had high specificity (85%) but very low sensitivity (10%). Ultrasound use declined after 2019, while CT and MRI utilization increased.
conclusionThe histological landscape of PGTs has shifted, with WT now emerging as the most common benign neoplasm. While ultrasonography remains the primary imaging modality, CT and MRI are increasingly preferred due to their superior diagnostic accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.